Baxter Guides FY Adj EPS $1.95-$2.15, Setting the Bar for 2026
BAX sits 60% above its 52-week low of $15.73.
Summary
Baxter International issued full-year adjusted EPS guidance of $1.95 to $2.15, providing the first official profit target for 2026. The company now sees 2026 reported sales from continuing operations up 3%-4%, compared to its prior outlook of flat to up 1%. The guidance follows the July 14 segment consolidation from three to two units, suggesting management sees enough visibility to quantify the restructuring benefits. With shares at $25.20, the midpoint implies a P/E of roughly 12x, which will be scrutinized against peer med-tech valuations. No revenue or margin assumptions were disclosed, leaving the quality of the earnings outlook open to interpretation.
At the time of this announcement, BAX was trading at $25.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.8B. The 52-week trading range was $15.73 to $29.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.